Search Results



Find ALL words: kras
Found 577 documents, showing 1 - 10.
[1-10]  [11-20]  [21-30]  [31-40]  [41-50]  [Next >>]
Help
  1. KRAS gene mutation status and sensitivity to pemetrexed: A retrospective analysis. | 2013 ASCO Annual Meeting Abstracts
    ... : Background: KRAS is the most frequently mutated oncogene (25%) in lung adenocarcinoma. KRAS ...
    ... adenocarcinoma. KRAS mutations are a negative prognostic factor for survival. Recent phase II ...

  2. Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408). | 2013 ASCO Annual Meeting Abstracts
    ... of <i>KRAS</i> and <i>NRAS</i> mutations as predictive biomarkers ...
    ... analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab ( ...
    ... that mutations in KRAS exon 3 and NRAS exons 2 and 3 appeared to be predictive of pmab response ( ...
    ... in exon 4 of the KRAS and NRAS genes are predictive for pmab treatment and to determine the ...

  3. Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation. | 2013 ASCO Annual Meeting Abstracts
    ... features of KRAS-mutated colorectal tumors vary by site of mutation. | 2013 ASCO Annual ...
    ... : Background: KRAS mutations in codons 12 and 13 are present in approximately 40% of all ...
    ... subpopulation of KRAS-mutant colorectal tumors have not been clearly defined. Methods: Records ...

  4. Association of KRAS mutation with worse recurrence-free survival and site of metastatic progression after resection of hepatic colorectal metastases. | 2013 ASCO Annual Meeting Abstracts
    ... of KRAS mutation with worse recurrence-free survival and site of metastatic ...
    ... the influence of KRAS mutation status and outcome in patients (pts) with colorectal cancer. A ...
    ... worse outcome in KRAS mutated (MUT) pts who underwent resection of hepatic metastases ( ...

  5. Comparison of the characteristics and clinical course of 677 patients with metastatic lung cancers with mutations in KRAS codons 12 and 13. | 2013 ASCO Annual Meeting Abstracts
    ... with mutations in KRAS codons 12 and 13. | 2013 ASCO Annual Meeting Abstracts Search over 4,500 ...
    ... (pts) with KRAS mutant lung cancers have a shorter survival compared to pts with KRAS/EGFR ...
    ... to pts with KRAS/EGFR wild type tumors (Johnson et al, Cancer 2012). Whether outcomes for ...

  6. Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations. | 2013 ASCO Annual Meeting Abstracts
    ... cancer selected by KRAS mutations. | 2013 ASCO Annual Meeting Abstracts Search over 4,500 ...
    ... cancer selected by KRAS mutations. Sub-category: Metastatic Non-small Cell Lung Cancer ...
    ... : Background: KRAS mutations are present in 20% of NSCLC and are associated with primary ...
    ... to erlotinib (E). KRAS mutations result in constitutive activation of the Ras/Raf/MEK/ERK ...

  7. Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies. | 2013 ASCO Annual Meeting Abstracts
    ... of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR ...
    ... : Although KRAS and EGFR extracellular domain acquired mutations were detected in two ...
    ... of acquired KRAS and EGFR mutations in cfDNA from CRC patients (pts) treated with anti-...

  8. Evaluation of the prognostic/predictive role of tumor EGFR and KRAS mutations in Greek metastatic non-small cell lung cancer patients treated with first-line chemotherapy. | 2013 ASCO Annual Meeting Abstracts
    ... of tumor EGFR and KRAS mutations in Greek metastatic non-small cell lung cancer patients ...
    ... : Background: KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC) ...
    ... /predictive role of KRAS in advanced NSCLC, with conflicting results among small studies. Recent ...

  9. Genetic and molecular biomarker characterization of KRAS mutant non-small cell lung carcinoma (NSCLC) tumors. | 2013 ASCO Annual Meeting Abstracts
    ... of KRAS mutant non-small cell lung carcinoma (NSCLC) tumors. | 2013 ASCO Annual ...
    ... in a subset of KRAS mutant NSCLC lines. This study aimed to evaluate the frequency of KRAS, ...
    ... the frequency of KRAS, LKB1 and BRG1 mutations in NSCLC tumors; and determine whether KRAS ...

  10. Comparing KRAS mutation testing by pyrosequencing versus allele specific primary extension methods in colorectal cancer specimens. | 2013 ASCO Annual Meeting Abstracts
    ... KRAS mutation testing by pyrosequencing versus allele specific primary extension methods ...
    ... : Background: KRAS mutation status is an important clinical variable for targeting treatment ...
    ... 12 or 13 of the KRAS gene. Our institutional molecular pathology laboratory performs ...
Results Pages:  [1-10]  [11-20]  [21-30]  [31-40]  [41-50]  [Next >>]